Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00859469 · ClinicalTrials.gov registry record · Phase 2
Eloxatin® Plus Gemcitabine Chemotherapy for Mesothelioma
A Phase 2 study of Mesothelioma, sponsored by Columbia University.
- Completed
- Registry status
- Phase 2
- Development phase
- 29
- Enrollment target
- 1
- Study location
NCT00859469: Completed Phase 2 study of Mesothelioma, sponsored by Columbia University.
NCT00859469 is a Phase 2 study of Mesothelioma that has completed, run by Columbia University. The registered enrollment target is 29 participants, below the 197-participant average among 46 other Mesothelioma trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00859469, a Phase 2 study of Mesothelioma, has completed, sponsored by Columbia University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 29 participants
- Enrollment target
- 1
- Study location
Study Summary
In patients with pleural or peritoneal mesothelioma, what is the response rate to combined Oxaliplatin (ELOXATIN®) and Gemcitabine chemotherapy?
Primary Outcome
Radiologic response by RECIST criteria will be compared between baseline and at 2 months. Disease assessment: Two objective status determinations of CR before progression are required for a best response of CR. Two determinations of PR or better before progression, but not qualifying for a CR, are required for a best response of PR. Two determinations of stable/no response or better before progression, but not qualifying as CR or PR are required for a best response of stable/no response.
Conditions Studied
Interventions
- DRUG Oxaliplatin
- DRUG Gemcitabine
Study Locations (1)
New York
- Columbia University Medical Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2004-04 |
| Est. Completion | 2013-03 |
| Phase | Phase 2 |
What the finished NCT00859469 record still lists
NCT00859469 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 29 participants, a relatively small participant target, below the 197-participant average among 46 other Mesothelioma trials with a reported enrollment target (85% lower).
The record links to 1 condition, with Mesothelioma appearing as the primary indexed condition, and to 2 interventions - of which Oxaliplatin is the first listed.
NCT00859469 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT00859469 about?
NCT00859469 is a clinical study titled "Eloxatin® Plus Gemcitabine Chemotherapy for Mesothelioma". In patients with pleural or peritoneal mesothelioma, what is the response rate to combined Oxaliplatin (ELOXATIN®) and Gemcitabine chemotherapy?
What is the current status of trial NCT00859469?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 29 participants. The study started on 2004-04. Estimated completion is 2013-03.
What conditions does trial NCT00859469 study?
This clinical trial studies the following conditions: Mesothelioma.
What interventions are being tested in trial NCT00859469?
The interventions under investigation include: Oxaliplatin (DRUG), Gemcitabine (DRUG).
Who is sponsoring clinical trial NCT00859469?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00859469 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Mesothelioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00859469's enrollment target sits among peer trials
29 41st of 46 higher than 6 of 46 other Mesothelioma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Mesothelioma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Sacituzumab Govitecan in People With Mesothelioma
RECRUITING · Phase 2
-
Olaparib in Patients With HRD Malignant Mesothelioma
RECRUITING · Phase 2
-
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
RECRUITING · Phase 2
-
MAGIC AKI: Magnesium for the Prevention of HIOC-Associated AKI
RECRUITING · Phase 2
-
18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
RECRUITING · Phase 2
-
A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal Mesothelioma
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02429557 · 29 participants · Phase 1
Hemodynamic Mechanisms of Abdominal Compression in the Treatment of Orthostatic Hypotension in Autonomic Failure
- NCT02568878 · 29 participants · Phase 3
Creatine for Depressed Male and Female Methamphetamine Users
- NCT03014401 · 29 participants · NA
The Effect of Adipose-Derived Stem Cells for Knee Osteoarthritis
- NCT03128996 · 29 participants · Phase 1
Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia